biote Corp.
NASDAQ:BTMDMedical - Care Facilities
+$0.01 today
- Market cap
- $54.25M
- Beta
- 1.66
- P/E (TTM)
- 4.5
- EPS (TTM)
- $0.51
Volume 0.11M
Average 0.25M
BTMD EBITDA Margin
EBITDA as a percentage of revenue.
biote Corp.NASDAQ: BTMD
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to 14.0%
EBITDA Margin was 14.0% in Q1 FY2026, down 29.3 pp from a year earlier. On a trailing-twelve-month basis it was 19.8%, down 6.9 pp year over year. Over 3 fiscal years it widened by 22.8 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 3 analysts of 8.1% for the fiscal year ending Dec 2026, down from 27.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 14.0%-5.4 pp QoQ
- Last fiscal yearDec 2025
- 27.6%+19.7 pp YoY
- LTMMar 2026
- 19.8%-6.9 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -29.3 pp | -11.2 pp | +18.1 pp |
| 1 year | +19.7 pp | -19.5 pp | -39.3 pp |
| 3 years | +22.8 pp | -9.1 pp | -31.9 pp |
| 5 years | -9.7 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 27.6%
- Year-over-year change
- +19.7pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.6% | +19.7pp |
| FY2024 | 2024-12-31 | 7.9% | -13.4pp |
| FY2023 | 2023-12-31 | 21.3% | +16.5pp |
| FY2022 | 2022-12-31 | 4.8% | -21.0pp |
| FY2021 | 2021-12-31 | 25.8% | — |
EBITDA Margin vs competitors
How BTMD compares with its peers on the latest reported figures
- BTMD's LTM Mar 2026 EBITDA Margin of 19.8% is the 2nd highest of the 8 companies compared; the peer median is -859.3%.
- Its year-over-year change of -6.9 pp is the 5th highest of 7, against a peer median of +0.4 pp.
- Over three fiscal years its change of +22.8 pp compares with a peer median of -12.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 27.2% | +185.8 pp | +103.2 pp | |
| LTM Mar 2026 | 19.8% | -6.9 pp | +22.8 pp | |
| LTM Mar 2026 | 5.2% | +4.5 pp | -5.1 pp | |
| LTM Mar 2026 | -4.0% | -3.6 pp | -19.7 pp | |
| LTM Mar 2026 | -859.3% | +600.4 pp | +13170.1 pp | |
| LTM Mar 2026 | -1105.5% | -974.2 pp | -1158.7 pp | |
| LTM Mar 2026 | -3650.0% | — | — | |
| FY2025 | -125425.9% | -77690.7 pp | -122786.1 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
ACTUActuate Therapeutics Inc | FY2025 | — | — | — |
| Peer median (excluding BTMD) | -859.3% | +0.4 pp | -12.4 pp | |
Competitors are the stored peer set for BTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 139.4M | 164.96M | 185.36M | 197.19M | 192.22M |
| Cost of Revenue | 48.82M | 54.58M | 57.88M | 58.13M | 58.13M |
| Gross Profit | 90.58M | 110.38M | 127.48M | 139.06M | 134.09M |
| Gross Margin | 65.0% | 66.9% | 68.8% | 70.5% | 69.8% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 53.96M | 171.1M | 98.83M | 107.45M | 94.97M |
| Operating Expenses | 56.02M | 171.1M | 98.83M | 107.45M | 94.97M |
| Depreciation & Amortization | 1.4M | 2.2M | 794K | 3.57M | 3.67M |
| EBITDA | 35.98M | 7.96M | 39.54M | 15.59M | 53.12M |
| EBITDA Margin | 25.8% | 4.8% | 21.3% | 7.9% | 27.6% |
| Operating Income | 34.56M | (60.72M) | 28.66M | 31.61M | 39.12M |
| Operating Margin | 24.8% | -36.8% | 15.5% | 16.0% | 20.4% |
| Interest Income | 0 | 0 | 0 | 0 | 900K |
| Interest Expense | 1.67M | 4.05M | 6.36M | 11M | 11.86M |
| Other Income / Expenses | (1.66M) | 62.43M | (28.78M) | (30.6M) | (1.54M) |
| Income Before Tax | 32.91M | 1.71M | (123K) | 1.02M | 37.58M |
| Pre-Tax Margin | 23.6% | 1.0% | -0.1% | 0.5% | 19.6% |
| Income Tax Expense | 286K | 388K | 2.68M | 970K | 5.99M |
| Net Income | 32.62M | (969K) | 3.32M | 3.16M | 27.05M |
| Net Margin | 23.4% | -0.6% | 1.8% | 1.6% | 14.1% |
| EPS (Basic) | (0.87) | 0.16 | 0.13 | 0.09 | 0.86 |
| EPS (Diluted) | (0.87) | 0.16 | 0.13 | 0.09 | 0.74 |
| Weighted Avg Shares | 7.57M | 8.06M | 25.71M | 34.27M | 31.28M |
| Weighted Avg Shares (Diluted) | 7.57M | 8.06M | 25.71M | 34.27M | 36.67M |
biote Corp.
NASDAQ:BTMD
Intrinsic Alpha fair value
Locked
Current Price
$1.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.